Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nedaplatin and 5-FU with Radiation in Esophageal Cancer
NCT00197444Phase 2Completed
- Sponsor
- Hamamatsu University School of Medicine
- Start
- Jan 2003
- Primary completion
- Sep 2008
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nedaplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Hamamatsu University School of Medicine. Primary endpoint: Objective Response Rate at 3 months. Started Jan 2003; status: completed.
02
Drugs
nedaplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT00197444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00197444.